S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:IXHL

Incannex Healthcare - IXHL News Today

$5.52
+0.06 (+1.10%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.35
▼
$5.61
50-Day Range
$3.43
▼
$6.50
52-Week Range
$3.26
▼
$90.00
Volume
8,038 shs
Average Volume
131,106 shs
Market Capitalization
$334.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Incannex Healthcare News Delivered to You Automatically

Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.

IXHL Media Mentions By Week

IXHL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IXHL
News Sentiment
▼
1.25

0.64
▲
Average
Medical
News Sentiment

IXHL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IXHL Articles
This Week
▼
1

2
▲
IXHL Articles
Average Week



SourceHeadline
proactiveinvestors.com.au logoJune quarter: biotech companies buck trend that says sector moves slowly
proactiveinvestors.com.au - August 11 at 1:26 AM
finance.yahoo.com logoDo Institutions Own Incannex Healthcare Limited (ASX:IHL) Shares?
finance.yahoo.com - August 10 at 8:22 PM
proactiveinvestors.com logoIncannex Healthcare partners with R&D organisation Curia to scale-up manufacture of drug targeting traumatic brain injury
proactiveinvestors.com - August 2 at 12:33 AM
proactiveinvestors.com logoIncannex agrees deal with Curia to scale-up manufacture of traumatic brain injury drug
proactiveinvestors.com - August 2 at 12:33 AM
wsj.com logoIncannex Healthcare Ltd. ADR
wsj.com - July 23 at 10:52 AM
msn.com logoIncannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug
msn.com - July 21 at 10:34 AM
seekingalpha.com logoIncannex adds over 19% with positive data for sleep apnea candidate
seekingalpha.com - June 3 at 11:01 AM
markets.businessinsider.com logoIncannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea
markets.businessinsider.com - June 3 at 11:01 AM
finance.yahoo.com logoIncannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
finance.yahoo.com - June 3 at 11:01 AM
benzinga.com logoIncannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea: Incannex Healthcare Limited (NASDAQ: IXHL)
benzinga.com - May 24 at 11:15 PM
benzinga.com logoIncannex Gets Positive Feedback On Pre-IND Meeting With The FDA For Dronabinol Based Drug For Obstructive Sleep Apnea
benzinga.com - May 17 at 1:12 PM
proactiveinvestors.com logoIncannex Healthcare has positive FDA pre-IND meeting on IHL-42X for obstructive sleep apnoea
proactiveinvestors.com - May 16 at 9:42 PM
proactiveinvestors.com logoIncannex Healthcare study targeting concussion reveals neuro-protective properties of treatment
proactiveinvestors.com - May 10 at 11:50 PM
finance.yahoo.com logoIncannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion
finance.yahoo.com - May 10 at 8:48 AM
proactiveinvestors.com logoIncannex Healthcare's IHL-216A treatment observed to have neuroprotective effect in rodent model of sports concussion
proactiveinvestors.com - May 9 at 10:46 PM
finance.yahoo.com logoIncannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M
finance.yahoo.com - April 28 at 9:55 AM
finance.yahoo.com logoQuarterly Activities Report and Appendix 4C Cash Flow Statement
finance.yahoo.com - April 28 at 9:55 AM
investing.com logoIncannex Healthcare Ltd ADR (IXHL)
investing.com - March 31 at 11:14 PM
seekingalpha.com logoIncannex to acquire APIRx Pharma in a deal worth over $93 million
seekingalpha.com - March 24 at 11:50 AM
markets.businessinsider.com logoIncannex Healthcare To Acquire APIRx Pharmaceuticals For $93.3M
markets.businessinsider.com - March 24 at 11:50 AM
proactiveinvestors.com logoIncannex Healthcare moves to acquire biotech company APIRx Pharmaceuticals USA
proactiveinvestors.com - March 24 at 1:49 AM
finance.yahoo.com logoIncannex Healthcare Limited (IXHL)
finance.yahoo.com - March 18 at 9:11 AM
proactiveinvestors.com logoIncannex Healthcare targeting $120 billion global addressable market with cannabinoid and psychedelic therapeutics
proactiveinvestors.com - March 17 at 12:23 AM
proactiveinvestors.com logoIncannex Healthcare welcomes positive preliminary data from obstructive sleep apnoea trial
proactiveinvestors.com - March 17 at 12:23 AM
finance.yahoo.com logoWhy Incannex Healthcare Stock Crashed Today
finance.yahoo.com - March 16 at 7:23 PM
seekingalpha.com logoOraSure Technologies leads postmarket gainers; Incannex Healthcare top loser
seekingalpha.com - March 15 at 6:19 PM
investorplace.com logoIXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too
investorplace.com - March 15 at 3:01 PM
msn.com logoWhat's Going On With Incannex Healthcare's Stock Today?
msn.com - March 15 at 1:19 PM
Get Incannex Healthcare News Delivered to You Automatically

Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:IXHL) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.